Latest news | MiniMed begins trading on Nasdaq Global Select Market - Read more »
MiniMed™ 780G insulin pump with Guardian™ 4 Sensor
Our most advanced insulin pump system with SmartGuard™ automation for self-adjusting basal delivery with autocorrection dosing.
Learn more
InPen™ Smart MDI System^
The Smart MDI system^ combines the power of our latest innovation in continuous glucose monitoring (CGM), Guardian™ 4 Smart* CGM system with the InPen™ Smart** Insulin Pen System.
Learn more
We are 1 company instead of 2
You only need to contact us.
For more than 40 years, MiniMed has committed to drive innovation, including new insulin delivery solutions that make life easier by reducing the burden of diabetes and deliver strong clinical outcomes.
Hear from our community
“No more missing out on what life has to offer! We’re so blessed with the technology we have access to these days and that’s allowed me to travel the world by myself for almost 8 months with very little trouble and stress whatsoever.”
MiniMed™ 780G system user
Our solutions and services
Automated self-adjusting insulin pump
The MiniMed 780G system^ automatically adjusts insulin delivery to help you reach glycaemic targets with less effort and zero calibrations*1,2.
Learn more
CareLink™ systems
The portfolio of CareLink™ software reports can identify trends, track daily activities and help your care partner to identify patterns and behaviour which may be affecting you.
Learn more
Education & training
Whether it is learning the basics of diabetes, counting carbohydrates, or learning how to effectively use your device, our modules are designed to give you the support you need.
Learn more
ALWAYS FOLLOW THE DIRECTIONS FOR USE.
The MiniMed™ 780G system is indicated for use by individuals aged 2 years and older with insulin-requiring diabetes, whose total daily dose of insulin is 6 units per day or more. The MiniMed™ 780G system is intended for the continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed™ 780G system includes SmartGuard™ technology, which can be programmed to provide an automatic adjustment of insulin delivery based on continuous glucose monitoring (CGM) and can suspend the delivery of insulin when the SG value falls below, or is predicted to fall below, predefined threshold values.
Automated insulin delivery is made possible through combining MiniMed™ insulin pump and continuous glucose monitoring technology. Some user interaction required. Individual responses to the treatment can and do vary. Consult a healthcare professional to see if this product is suitable for you.
The Guardian™ 4 sensor is intended for use with the Guardian™ 4 transmitter and indicated for measuring interstitial-fluid glucose levels in people with insulin-requiring diabetes where self-monitoring of blood glucose (SMBG) is indicated. The sensor is a single-use, disposable device intended to be paired with a compatible transmitter as part of a continuous glucose monitoring (CGM) system for the management of diabetes. The sensor and transmitter CGM system is a non-adjunctive system that may replace fingerstick blood glucose readings for treatment decisions. The sensor is indicated for single patient use in persons 2 years and older with diabetes mellitus. The sensor is intended for insertion into the back of the upper arm or the upper buttocks in persons ages 2 through 17 years. The sensor is intended for insertion into the back of the upper arm or the abdomen in persons ages 18 years and older. If glucose values do not match expectations, use a blood glucose meter to make diabetes treatment decisions.
^Components sold separately* A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions.
1. Carlson, A.L. et al. Safety and Glycemic Outcomes During the Minimed Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. DIABETES TECHNOLOGY & THERAPEUTICS. Vol 24, No. 3 (2022) 1-12.
2. Da Silva J, et al. Real-world Performance of the Minimed 780G System: First Report of Outcomes from 4'120 Users. Diabetes Technol Ther. 2021; doi: 10.1089/dia.2021.0203.
3. Abraham SB, et al. Improved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts. Journal of Diabetes Science and Technology 2021; 15(1):91–97
4. Smith M, et al, E5 , SIPs Improve Time Below Range in MDI Therapy, AMCP Congress 2020